Back to Search
Start Over
Liver X receptor: a potential target in the treatment of atherosclerosis
- Source :
- Expert Opinion on Therapeutic Targets. 26:645-658
- Publication Year :
- 2022
- Publisher :
- Informa UK Limited, 2022.
-
Abstract
- Liver X receptors (LXRs) are master regulators of atherogenesis. Their anti-atherogenic potential has been attributed to their role in the inhibition of macrophage-mediated inflammation and promotion of reverse cholesterol transport. Owing to the significance of their anti-atherogenic potential, it is essential to develop and test new-generation LXR agonists, both synthetic and natural, to identify potential LXR-targeted therapeutics for the future.This review describes the role of LXRs in atherosclerotic development, and provides a summary of LXR agonists and future directions for atherosclerosis research. We searched PubMed, Scopus, and Google Scholar for relevant reports, from last 10 years, using atherosclerosis, liver X receptor, and LXR agonist as keywords.LXRα has gained widespread recognition as a regulator of cholesterol homeostasis and expression of inflammatory genes. Further research using models of cell type-specific knockout and specific agonist-targeted LXR isoforms is warranted. Enthusiasm for therapeutic value of LXR agonists has been tempered due to LXRα-mediated induction of hepatic lipogenesis. LXRα agonism and LXRβ targeting, gut-specific inverse LXR agonists, investigations combining LXR agonists with other lipogenesis-mitigating agents, like IDOL antagonists and synthetic HDL, and targeting ABCA1, M2 macrophages, and LXRα phosphorylation remain as promising possibilities.
Details
- ISSN :
- 17447631 and 14728222
- Volume :
- 26
- Database :
- OpenAIRE
- Journal :
- Expert Opinion on Therapeutic Targets
- Accession number :
- edsair.doi.dedup.....af27827c0b45d2f3dff2235a1348dda7